Picard Medical will enhance its Total Artificial Heart design with new Connector Covers for increased patient comfort and safety.
Quiver AI Summary
Picard Medical, Inc., the parent company of SynCardia Systems, has announced it will incorporate "Connector Covers," an FDA-cleared accessory, into the design of its SynCardia Total Artificial Heart (STAH) starting January 15, 2026. These covers will enhance patient comfort and safety by providing additional protection over the metal release buttons on the STAH's connectors. The company emphasizes its commitment to patient safety and quality of life, and all sales and clinical staff have received training ahead of the rollout. SynCardia remains the only commercially available total artificial heart technology in the U.S. and Canada, with over 2,100 implants performed globally.
Potential Positives
- Announcement of the incorporation of CPC1 “Connector Covers” into the SynCardia Total Artificial Heart design enhances patient comfort and safety, demonstrating innovation and commitment to quality.
- The rollout of this improvement into standard clinical practice is set to begin shortly, indicating prompt implementation of advancements in patient care.
- All sales and clinical staff have completed training prior to the rollout, ensuring readiness and support for clinicians and patients, which may enhance operational effectiveness.
- The SynCardia Total Artificial Heart remains the only commercially available artificial heart in the U.S. and Canada, highlighting the company's leadership in this niche market.
Potential Negatives
- Incorporating the CPC1 Connector Covers indicates a response to potential safety or reliability concerns regarding existing product design, which could raise questions about the previous functionality of the SynCardia Total Artificial Heart.
- The need for additional training and support materials for clinical teams and patients may suggest that the product has complexities that could affect user confidence or ease of use.
- The forward-looking statements section underscores the inherent risks and uncertainties associated with future outcomes, which may concern investors and stakeholders regarding the company's plans and projections.
FAQ
What is Picard Medical's announcement about?
Picard Medical announced the incorporation of CPC1 “Connector Covers” into the SynCardia Total Artificial Heart design to enhance patient safety and comfort.
When will the new Connector Covers be available?
The CPC Connector Covers are expected to be rolled out in standard clinical practice in the U.S. starting January 15, 2026.
How do Connector Covers improve safety for patients?
The Connector Covers provide an extra layer of protection over the metal release buttons, enhancing safety during daily activities for patients using the STAH.
Who is involved in the rollout of the new design components?
All SynCardia sales and clinical staff have completed required training, and the company will assist hospital teams with training and implementation guidance.
What does the SynCardia Total Artificial Heart do?
The SynCardia Total Artificial Heart is an implantable system that performs the full functions of a failing or failed human heart for patients with end-stage heart failure.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$PMI Hedge Fund Activity
We have seen 8 institutional investors add shares of $PMI stock to their portfolio, and 0 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- HRT FINANCIAL LP added 244,086 shares (+inf%) to their portfolio in Q3 2025, for an estimated $2,074,731
- CITADEL ADVISORS LLC added 204,154 shares (+inf%) to their portfolio in Q3 2025, for an estimated $1,735,309
- CENTIVA CAPITAL, LP added 42,421 shares (+inf%) to their portfolio in Q3 2025, for an estimated $360,578
- XTX TOPCO LTD added 17,744 shares (+inf%) to their portfolio in Q3 2025, for an estimated $150,824
- JAIN GLOBAL LLC added 12,900 shares (+inf%) to their portfolio in Q3 2025, for an estimated $109,650
- UBS GROUP AG added 5,483 shares (+inf%) to their portfolio in Q3 2025, for an estimated $46,605
- MORGAN STANLEY added 5,060 shares (+inf%) to their portfolio in Q3 2025, for an estimated $43,010
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
TUCSON, Ariz., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems, LLC, maker of the world’s first total artificial heart approved by both the U.S. Food and Drug Administration (FDA) and Health Canada today announced that it would begin to incorporate an additional design component of an FDA-cleared accessory, CPC 1 “Connector Covers”, into its SynCardia Total Artificial Heart (STAH) design that is intended to provide comfort during daily activities while reinforcing system safety and reliability.
Specifically, the CPC Connector Covers will offer an extra layer of protection over the metal release buttons that are found on the STAH CPC connectors which externally connect SynCardia Drivers to the two pneumatic drive cannulas of the STAH ventricles. The rollout is expected to be incorporated into standard clinical practice for patients in the U.S. beginning January 15, 2026.
“Patient safety and quality of life are central to everything we do,” said Steve Langford, Senior Clinical Specialist at SynCardia Systems. “This enhancement reflects our ongoing commitment to practical improvements that support confidence and ease of use for both patients and clinicians.”
All SynCardia sales and clinical staff have completed the required training in advance of the rollout. SynCardia will work directly with hospital and clinical teams to provide training materials, implementation guidance, and support for existing patients as appropriate.
About Picard Medical, Inc.
Picard Medical, Inc. is the parent company of SynCardia Systems, LLC (“SynCardia”), the Tucson, Arizona–based leader with the only commercially available total artificial heart technology for patients with end-stage heart failure. SynCardia develops, manufactures, and commercializes the SynCardia Total Artificial Heart (“STAH”), an implantable system that assumes the full functions of a failing or failed human heart. It is the first artificial heart approved by both the FDA and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada. With more than 2,100 implants performed at hospitals across 27 countries, the SynCardia Total Artificial Heart is the most widely used and extensively studied artificial heart in the world. For more information, please visit
https://www.syncardia.com
.
References
1 Cold Products Company , a part of Dover (NYSE: DOV ) and a leading manufacturer of connection technologies used in liquid cooling of electronics.
Forward-Looking Statements
This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
Contact:
Investors
Eric Ribner
Managing Director
LifeSci Advisors LLC
[email protected]
Picard Medical, Inc./SynCardia Systems, LLC
[email protected]
General/Media
Brittany Lanza
[email protected]
